Decision to list anaesthesia small equipment and consumable devices supplied by Teleflex Medical New Zealand Ltd

Hospital devices

Decision

We are pleased to announce the approval of a listing agreement for anaesthesia small equipment and consumable devices (“Anaesthesia Products”) with Teleflex Medical New Zealand Ltd (“Teleflex”).

What we are doing

We are pleased to announce the approval of a listing agreement for Anaesthesia Small Equipment and Consumable devices (“Anaesthesia Products”) with Teleflex Medical New Zealand Ltd (“Teleflex”).

In summary, this will result in:

  • 457 Anaesthesia Products being listed in Part III of Section H of the Pharmaceutical Schedule from 1 May 2018.
  • National DHB savings estimated at $130,500 per annum on the purchase of these products, assuming no change to current usage levels or product mix.

This Agreement would supersede any existing DHB contracts with this supplier for the devices listed in Schedule One of the Agreement. 



Any changes to the original proposal?

This decision was subject to consultation on 07 February 2017. No changes were made to the listing agreement as a result of consultation feedback.


Who we think will be most interested

  • Suppliers and Wholesalers
  • DHB Staff
    • Clinical Engineers
    • Anaesthetists
    • Anaesthetic Technicians
    • Clinical staff involved with airway management and emergency respiratory resuscitation
    • Procurement Officers 


Details about this decision

In March 2017 PHARMAC issued a Request for Proposals for Anaesthesia Products. The RFP was for non-exclusive national agreements for listing on the Pharmaceutical Schedule.

The scope of the Anaesthesia Products category was defined as:

  • Airway visualisation devices and associated consumables
  • Stand-alone depth of anaesthesia monitoring systems and associated consumables
  • Consumable medical devices used for the purpose of:
    • Acute airway management
    • Anaesthesia gas delivery

Consumable medical devices included both single use items and defined-life multiple use items.

PHARMAC has been working with suppliers to seek provisional agreements.

DHB hospitals would continue to be able to choose which Anaesthesia Products they purchase, however would need to use this agreement should they choose to purchase Teleflex devices listed in the Pharmaceutical Schedule, effective from 1 May 2018.  

Teleflex have some products that are new to New Zealand DHBs and the Agreement would provide an increased range of Anaesthesia Products from which clinicians could choose.

Pricing for Anaesthesia Products, subject to any prior termination of the Agreement, would not be increased without prior consultation and approval by PHARMAC.

Teleflex will provide training and education services that will be tailored to suit the needs of individual DHBs in formats and at times as required by DHBs.

We intend to consult on proposed agreements for Anaesthesia Products with other suppliers over the next few months. 

The list of Teleflex Anaesthesia products will be available on PHARMAC's website from 1 May 2018, in both a PDF document and an Excel spreadsheet.


Our response to what you told us

We are grateful for the time people took to respond to this consultation. All consultation responses received were considered in their entirety in making a decision to approve the provisional agreements.

A summary of the main themes raised in feedback and our responses to the feedback received are set out below: 

Theme

Comment

Request for clarification of the impact of National Contracting on the range of devices available to clinicians.

Additional information was provided.

Request for confirmation that PHARMAC is expecting to contract with other companies for Anaesthesia Products

PHARMAC is expecting to contract with other companies for Anaesthesia Products

Request for clarification of the devices considered in scope for National Contracting of Anaesthesia Products.

Clarification provided

Feedback from DHB on the financial impact of the proposal

Noted

Feedback that no technical or resource impacts are anticipated as a result of the proposal.

Noted

If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.